Aktuelle smitsomme sygdomme

The Home Test to Treat program is virtual and offers at-home rapid tests, telehealth sessions, and at-home treatments to people nationwide. WebMD Health News…

The percentage of patients with a U09.9 diagnostic code in the year after a SARS-CoV-2 infection ranged from less than 4% in one region to more than 24% in another Medscape Medical News…

More than a third of young adults living in the US during the COVID-19 pandemic experienced anxiety and/or depression, an outcome that may be related to economic or social uncertainty. Medscape Medical News…

BackgroundInfluenza vaccination for children aged 6 months to 6 years is included in the national vaccination programme in Finland. Although all vaccines in the programme are free of charge, national coverage of influenza vaccination among children under 3 years and 3–6 years during 2020/21 was 43% and 35% respectively, with regional differences. AimTo assess factors underlying parental vaccination intention in order to increase influenza vaccine uptake among children. MethodsWe conducted a web-based survey among parents (n = 17,844) of randomly selected eligible children (aged 6 months–6 years) in February–March 2022 in five Finnish municipalities from regions of high and low coverage. Logistic regressions were used to determine associations between vaccination intention and e.g. sociodemographic factors, attitudes and knowledge. Linkage to the national vaccination register was used to confirm realisation of vaccination intention after the study. ResultsParticipation rate was 13% (n = 2,322 parents). Influenza knowledge, trust in official information, responding parent’s education level, adherence to the vaccination programme, number of children and changes in attitudes towards vaccination since COVID-19 were all associated with intention to vaccinate. Vaccination intention for children was 64%, and realised vaccination 51%. ConclusionDespite the low participation rate, both vaccinated and unvaccinated children were represented. Influenza vaccine uptake is not dependent on a single factor. Our results identified the need for open dialogue between parents and healthcare professionals, as the lack of vaccine being offered by healthcare professionals was the most reported reason for not vaccinating. …

\'A significant wave [of JN.1] has started here and could be blunted with a high booster rate and mitigation measures.\' WebMD Health News…

Though many people remain on the fence about getting the latest COVID vaccine booster, new research suggests a strong argument for getting the shot this winter. Medscape Medical News…

Patients residing in nursing homes may exhibit signs of long COVID that are missed. Medscape Medical News…

COVID-19 appears to be heading for a holiday season increase across most of the United States. WebMD Health News…

Two doses of an mRNA COVID-19 vaccine reduced hospitalizations and emergency department visits by 40%. Medscape Medical News…

Researchers suggest this provides further evidence of benefit of SARS-CoV-2 vaccination before or during pregnancy. Medscape Medical News…

BackgroundUnderstanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations against SARS-CoV-2 infection is a public health priority. A precise analysis of the rVE of monovalent and bivalent boosters given during the 2022 spring-summer and autumn-winter campaigns, respectively, in a defined population remains of interest. AimWe assessed rVE against hospitalisation for the spring-summer (fourth vs third monovalent mRNA vaccine doses) and autumn-winter (fifth BA.1/ancestral bivalent vs fourth monovalent mRNA vaccine dose) boosters. MethodsWe performed a prospective single-centre test-negative design case–control study in ≥ 75-year-old people hospitalised with COVID-19 or other acute respiratory disease. We conducted regression analyses controlling for age, sex, socioeconomic status, patient comorbidities, community SARS-CoV-2 prevalence, vaccine brand and time between baseline dose and hospitalisation. ResultsWe included 682 controls and 182 cases in the spring-summer booster analysis and 572 controls and 152 cases in the autumn-winter booster analysis. A monovalent mRNA COVID-19 vaccine as fourth dose showed 46.6% rVE (95% confidence interval (CI): 13.9–67.1) vs those not fully boosted. A bivalent mRNA COVID-19 vaccine as fifth dose had 46.7% rVE (95% CI: 18.0–65.1), compared with a fourth monovalent mRNA COVID-19 vaccine dose. ConclusionsBoth fourth monovalent and fifth BA.1/ancestral mRNA bivalent COVID-19 vaccine doses demonstrated benefit as a booster in older adults. Bivalent mRNA boosters offered similar protection against hospitalisation with Omicron infection to monovalent mRNA boosters given earlier in the year. These findings support immunisation programmes in several European countries that advised the use of BA.1/ancestral bivalent booster doses. …

This report describes the effectiveness of COVID-19 mRNA vaccines among infants and children aged 6 months-4 years.

This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses, against hospitalisation due to COVID-19 and COVID-19 related deaths in resident populations ≥50 years of age, living in the community.

The findings demonstrate how vaccine-induced T-cell responses could potentially reduce COVID-19 severity, the authors write. Medscape Medical News…

An emerging variant of COVID-19 called BA.2.86 that caused alarm earlier this summer has landed on the CDC\'s radar again. WebMD Health News…

Researchers have pinpointed a potential common link to the varying symptoms of long COVID and specific testing could solve the mystery. Medscape Medical News…

This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.

The first year of the COVID-19 pandemic is associated with a 50% decline in working memory and executive function among older adults, a new UK study suggests. Medscape Medical News…

IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March–June)- and Delta (June–December)-dominant periods, 2021. MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case–control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset. ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69–92) overall and 75% (95% CI: 42–90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18–74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57–98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose 

IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received 

We followed 4,081,257 Australian adults aged ≥ 65 years between November 2022 and May 2023 for COVID-19-specific mortality, when recombinant SARS-CoV-2 Omicron lineages (predominantly XB and XBB) as well as BA.2.75 were circulating. Compared with a COVID-19 booster targeting ancestral SARS-CoV-2 given > 180 days earlier, the relative vaccine effectiveness against COVID-19 death of a bivalent (ancestral/BA.1 or ancestral/BA.4-5) booster given 8 to 90 days earlier was 66.0% (95%CI: 57.6 to 72.2%) and that of a monovalent ancestral booster given 8 to 90 days earlier was 44.7% (95%CI: 23.9 to 59.7%). …

This report describes increases in cases of congenital syphilis during the COVID-19 pandemic.

A Mayo Clinic study found nearly 90% of patients with long COVID experience chest pain, but treatment for this condition is not yet standardized. Medscape Medical News…

\'This entire year has been really filled with patients that have been trying to get access to the clinic for a year. And they’re still struggling.\' Medscape Medical News…

The SARS-CoV-2 BA.2.86 Omicron subvariant was first detected in wastewater in Sweden in week 31 2023, using 21 highly specific markers from the 50 investigated. We report BA.2.86’s introduction and subsequent spread to all 14 regions performing wastewater sampling, and on 70 confirmed COVID-19 cases, along with the emergence of sublineages JN.1 and JN.2. Further, we investigated two novel mutations defining the unique BA.2.86 branching in Sweden. Our integrated approach enabled variant tracking, offering evidence for well-informed public health interventions. …

We observed a rebound in consumption of antibacterials for systemic use (ATC J01) in the community sector in the European Union/European Economic Area during 2021 and 2022, after an observed decrease between 2019 and 2020. The rates in 2022 returned to pre-COVID-19-pandemic levels and were exceeded in 13 countries. Although these patterns could partly be a result of changes in disease transmission during the study period, it could also reflect a lost opportunity to strengthen and reinforce prudent antibiotic use. …

De variantopdaterede covid-19-vacciner, som er rettet mod nyere varianter af coronavirus, og som er blevet givet siden oktober i år, giver god beskyttelse mod alvorlig sygdom.

Gargling and nasal rinsing were associated with a significant reduction in the hospitalization rate for people with COVID; if confirmed, the finding could be helpful in low-resource settings, says researcher. Medscape Medical News…

Though antivirals are critical for reducing severe COVID-19 symptoms, researchers suggested that the medication may not always be needed for milder cases. Medscape Medical News…

A 50% decline in working memory and executive function among older adults in the United Kingdom during the first year of the COVID-19 pandemic is linked to an increase in known risk factors for dementia. Medscape Medical News…

Despite our prevention efforts, some unlucky few may contract not just one of these viruses, but two at once or in close succession during the winter season. WebMD Health News…

Long COVID can exacerbate existing mental health disorders or cause new-onset psychiatric symptoms, but mental illness does not cause long COVID, experts say. Medscape Medical News…

Three years after infection most people could smell or taste effectively again, a new study found. Medscape Medical News…

This report describes declines in influenza vaccination coverage among health care personnel working in hospitals during the COVID-19 pandemic.

This report describes the percentage of health care personnel working in hospitals and nursing homes who received a flu vaccine and the percentage who received a COVID-19 vaccine.

Could antidepressants hold the key to treating long COVID? Medscape Medical News…

Lead researcher Ziyad Al-Aly, MD, spoke with Medscape about his team’s findings, what we know — and don’t — about long COVID, and what it means for physicians treating patients with the condition. Medscape Medical News…

A pair of new studies about long COVID have shed more light on the sometimes-disabling condition that affects millions of people in the United States. WebMD Health News…

\'There\'s an important opportunity here for regulators to understand there are still quite a number of businesses making problematic advertising claims.\' WebMD Health News…

The commonalities among people in the study who developed long COVID suggest that the condition\'s cause is the same regardless of which variant led to the initial infection. WebMD Health News…

BackgroundThe NHS Test and Trace (NHSTT) programme was established in May 2020 in England to deliver SARS-CoV-2 testing and contact tracing in order to identify infected individuals and reduce COVID-19 spread. To further control transmission, people identified as contacts were asked to self-isolate for 10 days and test only if they became symptomatic. From March 2021, eligibility criteria for PCR testing expanded to include asymptomatic contacts of confirmed cases. AimTo analyse testing patterns of contacts before and after the change in testing guidance in England to assess the impact on PCR testing behaviour with respect to symptom status and contact type. MethodsTesting and contact tracing data were extracted from the national data systems and linked. Subsequently, descriptive statistical analysis was applied to identify trends in testing behaviour. ResultsBetween 1 January and 31 July 2021, over 5 million contacts were identified and reached by contact tracers; 42.3% took a PCR test around the time they were traced. Overall positivity rate was 44.3% and consistently higher in symptomatic (60–70%) than asymptomatic (around 20%, March–June) contacts. The proportion of tests taken by asymptomatic contacts increased over time, especially after the change in testing guidance. No link was observed between uptake of PCR tests and vaccination coverage. Fully vaccinated contacts showed lower positivity (23.8%) than those with one dose (37.2%) or unvaccinated (51.0%). ConclusionAlmost 1 million asymptomatic contacts were tested for SARS-CoV-2, identifying 214,056 positive cases, demonstrating the value of offering PCR testing to this group. …

COVID-19 has no impact on disease activity, progression, or cognitive performance in patients with multiple sclerosis. Medscape Medical News…

Among Canadians, patients aged 80 years or older are the least likely to have a history of COVID-19 infection and the most likely to be hospitalized or die following infection, data indicate. Medscape Medical News…

With the exception of venous thromboembolism and pulmonary embolism events, the antiviral drug did not reduce the incidence of post-COVID-19 conditions in a study of nearly 10,000 US veterans. Medscape Medical News…

Physicians provided tips on how to increase rates of pregnant women receiving the COVID-19 booster. Medscape Medical News…

This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.

Researchers report endoscopic features and propose diagnostic criteria for post–COVID-19 cholangiopathy — one of the most serious long-term gastrointestinal consequences of COVID-19. Medscape Medical News…

CDC detected BA.2.86 variant in a traveler within days of being reported. Timely detection provides early warning of new COVID-19 variants entering the U.S.

COVID-19 increases the risk for Guillain-Barré syndrome sixfold, while getting the Pfizer mRNA vaccine lowers risk. Medscape Medical News…

Både forekomsten af RS-virus, covid-19 og kighoste er i stigning. Sæsonen for RS-virus er nu startet, mens kighoste-forekomsten fortsætter på et epidemisk højt niveau, og forekomsten af covid-19 er støt stigende. Det viser den integrerede overvågning fra Statens Serum Institut (SSI).